<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03657004</url>
  </required_header>
  <id_info>
    <org_study_id>Giessen</org_study_id>
    <nct_id>NCT03657004</nct_id>
  </id_info>
  <brief_title>Immunosuppressive Regimen on Changes in Renal Function and Transplant Rejection Rate in Patients With Lung Transplant</brief_title>
  <official_title>Impact of Switch of Immunosuppressive Regime on Changes in Renal Function and Transplant Rejection Rate in Patients With Lung Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Giessen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Giessen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This retrospective single-center analyzes the impact of switch of immunosuppressive regimen
      on renal function and transplant rejection rate in patients with lung transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lung transplantation (LTx) is the preferred treatment modality for patients with end-stage
      lung disease. However, despite significant advances in treatment after LTx, comorbidities and
      medical complications contribute to a major extend to the high morbidity and mortality rate.
      Chronic kidney disease is common in patients after lung transplantation, and a large
      proportion of these patients ultimately progress to end-stage renal disease requiring
      dialysis. Chronic calcineurin inhibitor nephrotoxicity is one of the major risk factors for
      the development of chronic kidney disease. Mammalian target of rapamycin (mTOR) inhibitors
      such as everolimus have been increasingly used in combination with calcineurin inhibitors to
      reduce nephrotoxicity. However, whether a mTOR inhibitor based immunosuppressive regime leads
      to lower chronic nephrotoxicity remains unknown. The aim of this study is to evaluate whether
      the switch of the standard immunosuppressive regime after LTx with
      mycophenolate/tacrolimus/prednisolon to everolimus/tacrolimus/prednisolon is associated with
      an improved long-term preservation of renal function without increase in rejection rate.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 29, 2018</start_date>
  <completion_date type="Actual">August 29, 2019</completion_date>
  <primary_completion_date type="Actual">August 29, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Long-term loss of renal function in patients with standard immunosuppressive regimen after LTx (mycophenolate/tacrolimus/prednisolon) compared to those who switch to a mammalian target of rapamycin inhibitor based immunosuppressive regime</measure>
    <time_frame>2003-2018</time_frame>
    <description>Renal function as measured by estimated glomerular filtration rate (Chronic Kidney Disease Epidemiology Collaboration formula)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of rejection (acute and chronic) in patients with standard immunosuppressive regimen after LTx (mycophenolate/tacrolimus/prednisolon) compared to those who switch to a mammalian target of rapamycin inhibitor based immunosuppressive regime</measure>
    <time_frame>2003-2018</time_frame>
    <description>Rejection as measured by histological assessment</description>
  </secondary_outcome>
  <enrollment type="Actual">145</enrollment>
  <condition>Lung Transplant; Complications</condition>
  <condition>Chronic Kidney Diseases</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients who underwent lung transplantation at the University Hospital Giessen and
        Marburg, Campus Giessen and Kerckhoff Clinic Bad Nauheim
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients who underwent lung transplantation at the University Hospital Giessen and
             Marburg, Campus Giessen and Kerckhoff Clinic Bad Nauheim

        Exclusion Criteria:

          -  Patients who died within 3 months after lung transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Werner Seeger, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital Giessen and Marburg, Department of Internal Medicine II</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Giessen and Marburg</name>
      <address>
        <city>Giessen</city>
        <state>Hessen</state>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Hellemons ME, Bakker SJ, Postmus D, Verschuuren EA, Erasmus ME, Navis G, van der Bij W. Incidence of impaired renal function after lung transplantation. J Heart Lung Transplant. 2012 Mar;31(3):238-43. doi: 10.1016/j.healun.2011.08.013. Epub 2011 Oct 5.</citation>
    <PMID>21975352</PMID>
  </results_reference>
  <results_reference>
    <citation>Guethoff S, Stroeh K, Grinninger C, Koenig MA, Kleinert EC, Rieger A, Mayr T, von Ziegler F, Reichart B, Hagl C, Schramm R, Kaczmarek I, Meiser BM. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results. J Heart Lung Transplant. 2015 May;34(5):634-42. doi: 10.1016/j.healun.2014.11.025. Epub 2014 Dec 9.</citation>
    <PMID>25701373</PMID>
  </results_reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 29, 2018</study_first_submitted>
  <study_first_submitted_qc>August 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2018</study_first_posted>
  <last_update_submitted>September 25, 2019</last_update_submitted>
  <last_update_submitted_qc>September 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Giessen</investigator_affiliation>
    <investigator_full_name>Faeq Husain</investigator_full_name>
    <investigator_title>Senior physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

